Anto Biosciences:  Anto is building the first multimodal foundation model for the human “second genome” — the gut microbiome — to predict how gut bacteria interact with drugs or food compounds, transforming the gut from a black box into a controllable variable. Powered by its own unique data generation pipeline, it delivers population-scale insights in hours, enabling safer, more effective products before clinical trials begin.

Celvion Therapeutics: Celvion is advancing AI-designed T cell therapies that integrate dual TCR and CAR systems to address tumor heterogeneity, with a primary focus on solid tumors. Cell engineering is driven by two proprietary computational platforms—one dedicated to TCR optimization and the other to identifying synergistic targets for combined CAR and TCR functionality.

KiraGen Bio: KiraGen develops multiplex-edited CAR-T therapies using AI-designed knockout combinations that block tumor suppression pathways, starting with GBM, to enable durable treatment across solid cancers.

LymeAlert: LymeAlert offers the first at-home tick test for Lyme disease with a paired AI-driven app that maps exposure hotspots using computer vision and federated learning.

MultiOmics: MultiOmics is building an AI-native platform to discover and validate plasma biomarkers for cancer and chronic disease, starting with breast cancer.

Noara Therapeutics: Noara is developing next-gen RNA therapeutics using AI and a proprietary high-throughput screening platform to treat chronic diseases.

Neoclease: Neoclease builds AI-designed gene editors custom-fit to individual genes, unlocking targets CRISPR can’t touch. Our lead program is a first-in-class LRRK2 knockout aimed at the root drivers of Parkinson’s disease progression.

Nervoid: Nervoid uses AI-driven discovery to develop new therapies that target the dopaminergic system and reduce opioid addiction and drug-seeking behavior.

Oralics: Oralics enables rapid, AI-powered detection of oral microbiome signatures via low-cost digital imaging—eliminating the need for sequencing in clinical and field settings.

RegulaBio: Regula Bio combines patient-derived multiomics with AI to map chronic disease pathways and identify therapeutic regulators that restore cellular health.

Riboway Therapeutics: Riboway decodes RNA biology with AI to precisely control protein function, making previously “undruggable” targets accessible through RNA-targeted therapeutics.

Semmelweis Labs: Semmelweis Labs prevents disease outbreaks in livestock using AI-powered aerosol sampling, helping farmers act before symptoms emerge and safeguarding food systems.

SequestBio: SequestBio uses an AI platform to predict cancer metastasis and design personalized therapies that reshape the tumor microenvironment for better patient outcomes.